Drug Profile
Research programme: monoamine reuptake inhibitors/mu opioid receptor agonists - Merck
Latest Information Update: 08 Feb 2017
Price :
$50
*
At a glance
- Originator Adolor Corporation
- Class
- Mechanism of Action Biogenic monoamine uptake inhibitors; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 16 Dec 2011 Discontinued for Pain in USA (PO)
- 12 Dec 2011 Adolor Corporation has been acquired and merged into Cubist Pharmaceuticals
- 20 Aug 2009 Early research in Pain in USA (PO)